| Description | This product is a human monoclonal antibody that reacts with CD19. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; WB |
| Application Notes | The antibody is recommended for detection of CD19 by ELISA, WB assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-CD19 Monoclonal Antibody (V3S-0622-YC2959) in ELISA
ELISA analysis of V3S-0622-YC2959 was performed by coating with Recombinant Human CD19 Protein. Then blocked with BSA, and incubated with Anti-Human CD19 Antibody (V3S-0622-YC2959). The HRP-conjugated anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 1 Anti-CD19 Monoclonal Antibody (V3S-0622-YC2959) in ELISA
Figure 2 Anti-CD19 Monoclonal Antibody (V3S-0622-YC2959) in WB
Western blot analysis of V3S-0622-YC2959 was performed by loading Recombinant Human CD19 Protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC2959 and HRP Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.2 μg)
Lane 3: Reducing antigen (0.3 μg)
Figure 2 Anti-CD19 Monoclonal Antibody (V3S-0622-YC2959) in WB
